nach oben

Erschienen in:

16.01.2020 | Brief Report

Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer

verfasst von: Ximena García, Andrés Elía, Lucrecia Galizzi, María May, Eunice Spengler, Paula Martínez Vázquez, Javier Burruchaga, Hugo Gass, Claudia Lanari, Caroline A. Lamb

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Expression of estrogen receptor alpha (ER) and/or progesterone receptor (PR) defines luminal breast cancer. Even though androgen (AR) and glucocorticoid receptors (GR) are highly expressed in luminal breast cancers, prognostic value remains uncertain and concomitant expression of these four hormone receptors is still unexplored.

Methods

Here, we evaluated ER, PR, AR, and GR expression, using immunohistochemistry, in a cohort of 169 breast cancer patients and correlated these findings with clinical and pathological parameters.

Results

We found that AR is more frequently expressed and at higher levels in the ER+PR− subset compared to ER+PR+ tumors. There were no significant differences in GR expression between tumor subsets. Moreover, most luminal tumors also expressed either AR or GR and most basal tumors were also negative for AR and GR.

Conclusion

These data suggest that targeting AR in ER+PR− tumors may represent a promising therapeutic alternative in hormonal refractory tumors.

Nur mit Berechtigung zugänglich

Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lonning PE, Borresen-Dale AL, Brown PO, Botstein D (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752CrossRefPubMed

Rakha EA, Reis-Filho JS, Ellis IO (2010) Combinatorial biomarker expression in breast cancer. Breast Cancer Res Treat 120(2):293–308. https://doi.org/10.1007/s10549-010-0746-x CrossRefPubMed

Rojas PA, May M, Sequeira GR, Elia A, Alvarez M, Martinez P, Gonzalez P, Hewitt S, He X, Perou CM, Molinolo A, Gibbons L, Abba MC, Gass H, Lanari C (2017) Progesterone receptor isoform ratio: a breast cancer prognostic and predictive factor for antiprogestin responsiveness. J Natl Cancer Inst 109(7):djw317CrossRefPubMedCentral

Ricciardelli C, Bianco-Miotto T, Jindal S, Butler LM, Leung S, McNeil CM, O'Toole SA, Ebrahimie E, Millar EKA, Sakko AJ, Ruiz AI, Vowler SL, Huntsman DG, Birrell SN, Sutherland RL, Palmieri C, Hickey TE, Tilley WD (2018) The magnitude of androgen receptor positivity in breast cancer is critical for reliable prediction of disease outcome. Clin Cancer Res 24(10):2328–2341. https://doi.org/10.1158/1078-0432.CCR-17-1199 CrossRefPubMed

McNamara KM, Kannai A, Sasano H (2018) Possible roles for glucocorticoid signalling in breast cancer. Mol Cell Endocrinol 466:38–50. https://doi.org/10.1016/j.mce.2017.07.004 CrossRefPubMed

Sahores A, Figueroa V, May M, Liguori M, Rubstein A, Fuentes C, Jacobsen BM, Elia A, Rojas P, Sequeira GR, Alvarez MM, Gonzalez P, Gass H, Hewitt S, Molinolo A, Lanari C, Lamb CA (2018) Increased high molecular weight FGF2 in endocrine-resistant breast cancer. Horm Cancer. https://doi.org/10.1007/s12672-018-0339-4 CrossRefPubMedPubMedCentral

Ades F, Zardavas D, Bozovic-Spasojevic I, Pugliano L, Fumagalli D, de Azambuja E, Viale G, Sotiriou C, Piccart M (2014) Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. J Clin Oncol 32(25):2794–2803. https://doi.org/10.1200/JCO.2013.54.1870 CrossRefPubMed

Lopez G, Costanza J, Colleoni M, Fontana L, Ferrero S, Miozzo M, Fusco N (2019) Molecular insights into the classification of luminal breast cancers: the genomic heterogeneity of progesterone-negative tumors. Int J Mol Sci. https://doi.org/10.3390/ijms20030510 CrossRefPubMedPubMedCentral

Harbeck N, Thomssen C, Gnant M (2013) St. Gallen 2013: brief preliminary summary of the consensus discussion. Breast Care 8(2):102–109. https://doi.org/10.1159/000351193 CrossRefPubMedPubMedCentral

10.

Dunnwald LK, Rossing MA, Li CI (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6. https://doi.org/10.1186/bcr1639 CrossRefPubMedPubMedCentral

11.

Kraby MR, Valla M, Opdahl S, Haugen OA, Sawicka JE, Engstrom MJ, Bofin AM (2018) The prognostic value of androgen receptors in breast cancer subtypes. Breast Cancer Res Treat 172(2):283–296. https://doi.org/10.1007/s10549-018-4904-x CrossRefPubMed

12.

Castellano I, Allia E, Accortanzo V, Vandone AM, Chiusa L, Arisio R, Durando A, Donadio M, Bussolati G, Coates AS, Viale G, Sapino A (2010) Androgen receptor expression is a significant prognostic factor in estrogen receptor positive breast cancers. Breast Cancer Res Treat 124(3):607–617. https://doi.org/10.1007/s10549-010-0761-y CrossRefPubMed

13.

Christenson JL, Trepel JB, Ali HY, Lee S, Eisner JR, Baskin-Bey ES, Elias AD, Richer JK (2018) Harnessing a different dependency: how to identify and target androgen receptor-positive versus quadruple-negative breast cancer. Horm Cancer 9(2):82–94. https://doi.org/10.1007/s12672-017-0314-5 CrossRefPubMedPubMedCentral

14.

Park S, Koo JS, Kim MS, Park HS, Lee JS, Lee JS, Kim SI, Park BW, Lee KS (2011) Androgen receptor expression is significantly associated with better outcomes in estrogen receptor-positive breast cancers. Ann Oncol 22(8):1755–1762. https://doi.org/10.1093/annonc/mdq678 CrossRefPubMed

15.

Qi JP, Yang YL, Zhu H, Wang J, Jia Y, Liu N, Song YJ, Zan LK, Zhang X, Zhou M, Gu YH, Liu T, Hicks DG, Tang P (2012) Expression of the androgen receptor and its correlation with molecular subtypes in 980 chinese breast cancer patients. Breast Cancer 6:1–8. https://doi.org/10.4137/BCBCR.S8323 CrossRefPubMed

16.

Micello D, Marando A, Sahnane N, Riva C, Capella C, Sessa F (2010) Androgen receptor is frequently expressed in HER2−positive, ER/PR−negative breast cancers. Virchows Arch 457(4):467–476. https://doi.org/10.1007/s00428-010-0964-y CrossRefPubMed

17.

Yu Q, Niu Y, Liu N, Zhang JZ, Liu TJ, Zhang RJ, Wang SL, Ding XM, Xiao XQ (2011) Expression of androgen receptor in breast cancer and its significance as a prognostic factor. Ann Oncol 22(6):1288–1294. https://doi.org/10.1093/annonc/mdq586 CrossRefPubMed

Titel: Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer
verfasst von: Ximena García
Andrés Elía
Lucrecia Galizzi
María May
Eunice Spengler
Paula Martínez Vázquez
Javier Burruchaga
Hugo Gass
Claudia Lanari
Caroline A. Lamb
Publikationsdatum: 16.01.2020
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 1/2020
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-020-05527-3

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Increased androgen receptor expression in estrogen receptor-positive/progesterone receptor-negative breast cancer

Abstract

Purpose

Methods

Results

Conclusion

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Extent of axillary surgery in inflammatory breast cancer: a survival analysis of 3500 patients

Cytotoxic T cell depletion with increasing epithelial abnormality in women with benign breast disease

Double reading of diffusion-weighted magnetic resonance imaging for breast cancer detection

Healthcare system distrust and the breast cancer continuum of care

Systemic therapy following craniotomy in patients with a solitary breast cancer brain metastasis

Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie